INCY vs XOMAP · P/E 14, rev $5.14B vs P/E 25, rev $28.5M
Incyte Corporation (INCY) versus XOMA Royalty Corporation (XOMAP) — a side-by-side from cached financials, not a winner call.
Incyte Corporation (INCY) is a biotechnology company listed on US.
XOMA Royalty Corporation (XOMAP) is a biotechnology company listed on NASDAQ.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Latest reported XOMAP revenue for 2024-12-31 was $28.5M. Net income was -$13.8M. Revenue was up 498.7% from 2023-12-31 to 2024-12-31. XOMAP currently screens at market cap $0 and trailing P/E 25.4.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. XOMAP currently screens at market cap $0 and trailing P/E 25.4.
Not investment advice. Open the INCY and XOMAP stock pages for the full models.
Not investment advice.